Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00109200 |
This is a continued access protocol to provide subjects who have completed Genentech, Inc. Study Q2143g, Q2195g, or Q2461g or Novartis Pharmaceuticals Corporation Study CIGE025 0010E1 with continued Xolair treatment. Subject eligibility will be based on disease severity and asthma deterioration upon withdrawal of Xolair treatment. Subjects whose last Xolair dose was <9 months prior to screening visit will continue with the same Xolair dosing regimen that they received in the previous Genentech or Novartis clinical study.
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: Xolair (omalizumab) |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Official Title: | A Continued Access Protocol to Provide Xolair® (Omalizumab) to Subjects With Severe Allergic Asthma Who Have Received Xolair Treatment in a Previous Investigational Study |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | Q2736g |
Study First Received: | April 26, 2005 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00109200 |
Health Authority: | United States: Food and Drug Administration |
Allergic Asthma Severe Allergic Asthma |
Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases |
Hypersensitivity, Immediate Asthma Omalizumab Respiratory Hypersensitivity |
Respiratory System Agents Immune System Diseases Bronchial Diseases Therapeutic Uses |
Anti-Asthmatic Agents Anti-Allergic Agents Pharmacologic Actions |